Significance of talin in cancer progression and metastasis

International Review of Cell and Molecular Biology

Volumn 289, Issue , 2011, Pages 117-147

  Desiniotis, Andreas ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Anoikis; Focal adhesions; Integrins; Invasion; Metastasis; Migration; Talin

Indexed keywords

ACTIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; BETA1 INTEGRIN; BETA3 INTEGRIN; BEVACIZUMAB; BIOLOGICAL MARKER; CILENGITIDE; DOXAZOSIN; DZ 50; ESTROGEN RECEPTOR; ETARACIZUMAB; FOCAL ADHESION KINASE; INTEGRIN; INTETUMUMAB; MATRIX METALLOPROTEINASE; MUTANT PROTEIN; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PAXILLIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; QUINAZOLINE DERIVATIVE; SILIBININ; SORAFENIB; SUNITINIB; TALIN; TALIN1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VIMENTIN;

ADVANCED CANCER; ANOIKIS; ANTIANGIOGENIC ACTIVITY; BOOK; BREAST CANCER; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; COLORECTAL CANCER; CYTOSKELETON; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE SILENCING; GLIOMA; GROWTH INHIBITION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MICROENVIRONMENT; NEOPLASM; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH;

EID: 79960149427     PISSN: 19376448     EISSN: 19376448     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386039-2.00004-3     Document Type: Chapter

References (216)

1. Acevedo V.D., Gangula R.D., et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007, 12:559-571.
2. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7:834-846.
3. Aguirre-Ghiso J.A., Estrada Y., et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003, 63:1684-1695.
4. Albelda S.M. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest. 1993, 68:4-17.
5. Arencibia J.M., Del Rio M., et al. Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation. Int. J. Oncol. 2005, 27:1617-1623.
6. Avraamides C.J., Garmy-Susini B., et al. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617.
7. Bakin A.V., Tomlinson A.K., et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 2000, 275:36803-36810.
8. Bakin A.V., Rinehart C., et al. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 2002, 115:3193-3206.
9. Barkan D., Green J.E., et al. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 2010, 46:1181-1188.
10. Beckerle M.C. The adhesion plaque protein, talin, is phosphorylated in vivo in chicken embryo fibroblasts exposed to a tumor-promoting phorbol ester. Cell Regul. 1990, 1:227-236.
11. Beckerle M.C., Miller D.E., et al. Activation-dependent redistribution of the adhesion plaque protein, talin, in intact human platelets. J. Cell Biol. 1989, 109:3333-3346.
12. Beekman K.W., Colevas A.D., et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin. Genitourin. Cancer 2006, 4:299-302.
13. Benning C.M., Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 2002, 62:597-602.
14. Bhowmick N.A., Ghiassi M., et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 2001, 12:27-36.
15. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
16. Bolos V., Gasent J.M., et al. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco. Targets Ther. 2010, 3:83-97.
17. Bouaouina M., Lad Y., et al. The N-terminal domains of talin cooperate with the phosphotyrosine binding-like domain to activate beta1 and beta3 integrins. J. Biol. Chem. 2008, 283:6118-6125.
18. Brown N.H., Gregory S.L., et al. Talin is essential for integrin function in Drosophila. Dev. Cell 2002, 3:569-579.
19. Burridge K., Chrzanowska-Wodnicka M. Focal adhesions, contractility, and signaling. Annu. Rev. Cell Dev. Biol. 1996, 12:463-518.
20. Calderwood D.A. Talin controls integrin activation. Biochem. Soc. Trans. 2004, 32:434-437.
21. Calderwood D.A., Zent R., et al. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J. Biol. Chem. 1999, 274:28071-28074.
22. Calderwood D.A., Yan B., et al. The phosphotyrosine binding-like domain of talin activates integrins. J. Biol. Chem. 2002, 277:21749-21758.
23. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4:118-132.
24. Chambers A.F., Groom A.C., et al. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
25. Chang H.Y., Nuyten D.S., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 2005, 102:3738-3743.
26. Chang L.C., Huang C.H., et al. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth. J. Biomed. Sci. 2005, 12:571-585.
27. Charlesworth A., Broad S., et al. The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125FAK and paxillin and cell proliferation. Oncogene 1996, 12:1337-1345.
28. Chiarugi P., Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 2008, 76:1352-1364.
29. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
30. Cianfrocca M.E., Kimmel K.A., et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 2006, 94:1621-1626.
31. Clark E.A., Brugge J.S. Integrins and signal transduction pathways: the road taken. Science 1995, 268:233-239.
32. Coates J.M., Galante J.M., et al. Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death. J. Surg. Res. 2010, 164:301-308.
33. Coll M.L., Rosen K., et al. Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells. Oncogene 2002, 21:2908-2913.
34. Cooper C.R., Bhatia J.K., et al. The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin. Exp. Metastasis 2002, 19:25-33.
35. Cordes N. Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury. Cancer Lett. 2006, 242:11-19.
36. Cordes N., Seidler J., et al. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006, 25:1378-1390.
37. Cram E.J., Clark S.G., et al. Talin loss-of-function uncovers roles in cell contractility and migration in C. elegans. J. Cell Sci. 2003, 116:3871-3878.
38. Critchley D.R., Gingras A.R. Talin at a glance. J. Cell Sci. 2008, 121:1345-1347.
39. Crowe D.L., Ohannessian A. Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation. BMC Cancer 2004, 4:18.
40. Cuellar D.C., Rhee J., et al. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Res. 2002, 22:1673-1679.
41. Delcommenne M., Tan C., et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 1998, 95:11211-11216.
42. Demers M.J., Thibodeau S., et al. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1. J. Cell. Biochem. 2009, 107:639-654.
43. Di Paolo G., Pellegrini L., et al. Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin. Nature 2002, 420:85-89.
44. Douma S., Van Laar T., et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
45. Enserink J.M., Christensen A.E., et al. A novel Epac-specific cAMP analogue demonstrates independent regulation of RAP1 and ERK. Nat. Cell Biol. 2002, 4:901-906.
46. Everley P.A., Krijgsveld J., et al. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol. Cell. Proteomics 2004, 3:729-735.
47. Finger E.C., Giaccia A.J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010, 29:285-293.
48. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
49. Fong A., Garcia E., et al. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 2003, 120:93-100.
50. Fornaro M., Manes T., et al. Integrins and prostate cancer metastases. Cancer Metastasis Rev. 2001, 20:321-331.
51. Frame M., Norman J. A tal(in) of cell spreading. Nat. Cell Biol. 2008, 10:1017-1019.
52. Friess H., Langrehr J.M., et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006, 6:285.
53. Frisch S.M., Vuori K., et al. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 1996, 134:793-799.
54. Fujita Y., Krause G., et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. 2002, 4:222-231.
55. Garcia-Alvarez B., de Pereda J.M., et al. Structural determinants of integrin recognition by talin. Mol. Cell 2003, 11:49-58.
56. Garrison J.B., Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res. 2006, 66:464-472.
57. Garrison J.B., Shaw Y.J., et al. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res. 2007, 67:11344-11352.
58. Giancotti F.G. Complexity and specificity of integrin signalling. Nat. Cell Biol. 2000, 2:E13-E14.
59. Giancotti F.G., Ruoslahti E. Integrin signaling. Science 1999, 285:1028-1032.
60. Gilles C., Polette M., et al. Vimentin contributes to human mammary epithelial cell migration. J. Cell Sci. 1999, 112:4615-4625.
61. Gingras A.R., Bate N., et al. The central region of talin has a unique fold that binds vinculin and actin. J. Biol. Chem. 2010, 285:29577-29587.
62. Goel H.L., Fornaro M., et al. Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta1 integrins. J. Cell Biol. 2004, 166:407-418.
63. Goel H.L., Li J., et al. Integrins in prostate cancer progression. Endocr. Relat. Cancer 2008, 15:657-664.
64. Goksoy E., Ma Y.Q., et al. Structural basis for the autoinhibition of talin in regulating integrin activation. Mol. Cell 2008, 31:124-133.
65. Goldmann W.H., Bremer A., et al. Native talin is a dumbbell-shaped homodimer when it interacts with actin. J. Struct. Biol. 1994, 112:3-10.
66. Graham T.R., Zhau H.E., et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008, 68:2479-2488.
67. Guarino M. Src signaling in cancer invasion. J. Cell. Physiol. 2010, 223:14-26.
68. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5:816-826.
69. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
70. Hallahan D., Kuchibhotla J., et al. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 1996, 56:5150-5155.
71. Hanna E., Quick J., et al. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009, 15:8-17.
72. Harris A.M., Warner B.W., et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J. Urol. 2007, 178:2176-2180.
73. Hendrix M.J., Seftor E.A., et al. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol. 1997, 150:483-495.
74. Horwitz A., Duggan K., et al. Interaction of plasma membrane fibronectin receptor with talin-a transmembrane linkage. Nature 1986, 320:531-533.
75. Huber M.A., Kraut N., et al. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
76. Hynes R.O. Integrins: a family of cell surface receptors. Cell 1987, 48:549-554.
77. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
78. Igishi T., Fukuhara S., et al. Divergent signaling pathways link focal adhesion kinase to mitogen-activated protein kinase cascades. Evidence for a role of paxillin in c-Jun NH(2)-terminal kinase activation. J. Biol. Chem. 1999, 274:30738-30746.
79. Irby R., Mao W., et al. Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential. Cell Growth Differ. 1997, 8:1287-1295.
80. Jagadeeswaran R., Surawska H., et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008, 68:132-142.
81. Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 2004, 90:561-565.
82. Jodele S., Blavier L., et al. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006, 25:35-43.
83. Juliano R.L., Reddig P., et al. Integrin regulation of cell signalling and motility. Biochem. Soc. Trans. 2004, 32:443-446.
84. Kanthou C., Tozer G.M. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int. J. Exp. Pathol. 2009, 903:284-294.
85. Katagiri K., Hattori M., et al. RAP1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Mol. Cell. Biol. 2000, 20:1956-1969.
86. Katagiri K., Hattori M., et al. RAP1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses. Mol. Cell. Biol. 2002, 22:1001-1015.
87. Khatib A.M., Kontogiannea M., et al. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res. 1999, 59:1356-1361.
88. Kim H.R., Lin H.M., et al. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999, 59:4148-4154.
89. Kim M., Carman C.V., et al. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003, 301:1720-1725.
90. Kim L.C., Song L., et al. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6:587-595.
91. Kinbara K., Goldfinger L.E., et al. Ras GTPases: integrins' friends or foes?. Nat. Rev. Mol. Cell Biol. 2003, 4:767-776.
92. Knudsen B.S., Miranti C.K. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J. Cell. Biochem. 2006, 99:345-361.
93. Kucik D.F. Rearrangement of integrins in avidity regulation by leukocytes. Immunol. Res. 2002, 26:199-206.
94. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J. Urol. 2003, 169:1520-1525.
95. Kyprianou N., Vaughan T.B., et al. Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?. Naunyn Schmiedebergs Arch. Pharmacol. 2009, 380:473-477.
96. Lafuente E.M., van Puijenbroek A.A., et al. RIAM, an Ena/VASP and Profilin ligand, interacts with RAP1-GTP and mediates RAP1-induced adhesion. Dev. Cell 2004, 7:585-595.
97. Lahm H., Andre S., et al. Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj. J. 2004, 20:227-238.
98. Larjava H., Plow E.F., et al. Kindlins: essential regulators of integrin signalling and cell-matrix adhesion. EMBO Rep. 2008, 9:1203-1208.
99. Law D.A., Nannizzi-Alaimo L., et al. Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. J. Biol. Chem. 1996, 271:10811-10815.
100. Lee Y.I., Kwon Y.J., et al. Integrin-linked kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition. Biochem. Biophys. Res. Commun. 2004, 316:997-1001.
101. Lee H.S., Lim C.J., et al. RIAM activates integrins by linking talin to ras GTPase membrane-targeting sequences. J. Biol. Chem. 2009, 284:5119-5127.
102. Legate K.R., Wickstrom S.A., et al. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009, 23:397-418.
103. Lewis J.M., Schwartz M.A. Mapping in vivo associations of cytoplasmic proteins with integrin beta 1 cytoplasmic domain mutants. Mol. Biol. Cell 1995, 6:151-160.
104. Li L., Ren C.H., et al. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol. 2003, 23:9389-9404.
105. Li R., Mitra N., et al. Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science 2003, 300:795-798.
106. Li D., Ding J., et al. Fibronectin promotes tyrosine phosphorylation of paxillin and cell invasiveness in the gastric cancer cell line AGS. Tumori 2009, 95:769-779.
107. Lim S.T., Mikolon D., et al. FERM control of FAK function: implications for cancer therapy. Cell Cycle 2008, 7:2306-2314.
108. Ling K., Doughman R.L., et al. Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions. Nature 2002, 420:89-93.
109. Ling K., Doughman R.L., et al. Tyrosine phosphorylation of type I gamma phosphatidylinositol phosphate kinase by Src regulates an integrin-talin switch. J. Cell Biol. 2003, 163:1339-1349.
110. Liotta L.A., Kohn E. Anoikis: cancer and the homeless cell. Nature 2004, 430:973-974.
111. Liu S., Calderwood D.A., et al. Integrin cytoplasmic domain-binding proteins. J. Cell Sci. 2000, 113:3563-3571.
112. Lo H.W., Hsu S.C., et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007, 67:9066-9076.
113. Ma Y.Q., Qin J., et al. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J. Cell Biol. 2008, 181:439-446.
114. Mackinnon A.C., Qadota H., et al. C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes. Curr. Biol. 2002, 12:787-797.
115. Martel V., Racaud-Sultan C., et al. Conformation, localization, and integrin binding of talin depend on its interaction with phosphoinositides. J. Biol. Chem. 2001, 276:21217-21227.
116. Mawji I.A., Simpson C.D., et al. A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res. 2007, 67:8307-8315.
117. Mawji I.A., Simpson C.D., et al. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J. Natl Cancer Inst. 2007, 99:811-822.
118. Mccleverty C.J., Lin D.C., et al. Structure of the PTB domain of tensin1 and a model for its recruitment to fibrillar adhesions. Protein Sci. 2007, 16:1223-1229.
119. McNeel D.G., Eickhoff J., et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 2005, 11:7851-7860.
120. Metalli D., Lovat F., et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am. J. Pathol. 2010, 176:2997-3006.
121. Monkley S.J., Pritchard C.A., et al. Analysis of the mammalian talin2 gene TLN2. Biochem. Biophys. Res. Commun. 2001, 286:880-885.
122. Montanez E., Ussar S., et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008, 22:1325-1330.
123. Moschos S.J., Drogowski L.M., et al. Integrins and cancer. Oncology (Williston Park) 2007, 21:13-20.
124. Moser M., Legate K.R., et al. The tail of integrins, talin, and kindlins. Science 2009, 324:895-899.
125. Mullamitha S.A., Ton N.C., et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 2007, 13:2128-2135.
126. Nabors L.B., Mikkelsen T., et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 2007, 25:1651-1657.
127. Nada S., Okada M., et al. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 1991, 351:69-72.
128. Nangia-Makker P., Honjo Y., et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156:899-909.
129. Nieswandt B., Moser M., et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J. Exp. Med. 2007, 204:3113-3118.
130. Oka N., Takenaka Y., et al. Galectins and urological cancer. J. Cell. Biochem. 2004, 91:118-124.
131. Olski T.M., Noegel A.A., et al. Parvin, a 42kDa focal adhesion protein, related to the alpha-actinin superfamily. J. Cell Sci. 2001, 114:525-538.
132. Orford K., Orford C.C., et al. Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J. Cell Biol. 1999, 146:855-868.
133. Orlichenko L.S., Radisky D.C. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin. Exp. Metastasis 2008, 25:593-600.
134. O'toole T.E., Mandelman D., et al. Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb. Science 1991, 254:845-847.
135. O'toole T.E., Katagiri Y., et al. Integrin cytoplasmic domains mediate inside-out signal transduction. J. Cell Biol. 1994, 124:1047-1059.
136. Owen J.D., Ruest P.J., et al. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol. Cell. Biol. 1999, 19:4806-4818.
137. Owens T.W., Valentijn A.J., et al. Apoptosis commitment and activation of mitochondrial Bax during anoikis is regulated by p38MAPK. Cell Death Differ. 2009, 16:1551-1562.
138. Oxley C.L., Anthis N.J., et al. An integrin phosphorylation switch: the effect of beta3 integrin tail phosphorylation on Dok1 and talin binding. J. Biol. Chem. 2008, 283:5420-5426.
139. Papagrigoriou E., Gingras A.R., et al. Activation of a vinculin-binding site in the talin rod involves rearrangement of a five-helix bundle. EMBO J. 2004, 23:2942-2951.
140. Parsons J.T. Focal adhesion kinase: the first ten years. J. Cell Sci. 2003, 116:1409-1416.
141. Partin J.V., Anglin I.E., et al. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br. J. Cancer 2003, 88:1615-1621.
142. Pearson G., Robinson F., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 2001, 22:153-183.
143. Perl A.K., Wilgenbus P., et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-193.
144. Persad S., Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev. 2003, 22:375-384.
145. Persad S., Attwell S., et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. USA 2000, 97:3207-3212.
146. Petrich B.G., Marchese P., et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J. Exp. Med. 2007, 204:3103-3111.
147. Playford M.P., Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004, 23:7928-7946.
148. Polette M., Gilles C., et al. Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin. Exp. Metastasis 1998, 16:105-112.
149. Przybylo J.A., Radisky D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int. J. Biochem. Cell Biol. 2007, 39:1082-1088.
150. Puklin-Faucher E., Sheetz M.P. The mechanical integrin cycle. J. Cell Sci. 2009, 122:179-186.
151. Radisky E.S., Radisky D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15:201-212.
152. Rajjayabun P.H., Garg S., et al. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001, 58:811-814.
153. Ramsay A.G., Marshall J.F., et al. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev. 2007, 26:567-578.
154. Rankin S., Hooshmand-Rad R., et al. Requirement for phosphatidylinositol 3'-kinase activity in platelet-derived growth factor-stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin. J. Biol. Chem. 1996, 271:7829-7834.
155. Ratnikov B.I., Partridge A.W., et al. Integrin activation by talin. J. Thromb. Haemost. 2005, 3:1783-1790.
156. Rennebeck G., Martelli M., et al. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Res. 2005, 65:11230-11235.
157. Rogalski T.M., Mullen G.P., et al. The UNC-112 gene in Caenorhabditis elegans encodes a novel component of cell-matrix adhesion structures required for integrin localization in the muscle cell membrane. J. Cell Biol. 2000, 150:253-264.
158. Roodink I., Leenders W.P. Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett. 2010, 299:1-10.
159. Roodink I., Verrijp K., et al. Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer 2009, 9:297.
160. Rosen K., Rak J., et al. Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism Ras induced resistance anoikis intestinal epithelial cells. J. Cell Biol. 2000, 149:447-456.
161. Rosen K., Shi W., et al. Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand. A novel mechanism Anoikis intestinal epithelial cells. J. Biol. Chem. 2002, 277:46123-46130.
162. Roy M., Marchetti D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J. Cell. Biochem. 2009, 106:200-209.
163. Sakamoto S., Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol. Aspects Med. 2010, 31:205-214.
164. Sakamoto S., Mccann R.O., et al. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res. 2010, 70:1885-1895.
165. Salgia R., Li J.L., et al. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J. Biol. Chem. 1995, 270:5039-5047.
166. Salgia R., Li J.L., et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 1999, 18:67-77.
167. Santimaria M., Moscatelli G., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 2003, 9:571-579.
168. Satoh T., Yang G., et al. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 2003, 97:1225-1233.
169. Schaller M.D., Hildebrand J.D., et al. Autophosphorylation of the focal adhesion kinase, pp 125FAK, directs SH2-dependent binding of pp60src. Mol. Cell. Biol. 1994, 14:1680-1688.
170. Schaller M.D., Hildebrand J.D., et al. Complex formation with focal adhesion kinase: a mechanism to regulate activity and subcellular localization of Src kinases. Mol. Biol. Cell 1999, 10:3489-3505.
171. Schlaepfer D.D., Mitra S.K., et al. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim. Biophys. Acta 2004, 1692:77-102.
172. Sen A., O'malley K., et al. Paxillin regulates androgen- and epidermal growth factor- induced MAPK signaling and cell proliferation in prostate cancer cells. J. Biol. Chem. 2010, 285:28787-28795.
173. Senetar M.A., Foster S.J., et al. Intrasteric inhibition mediates the interaction of the I/LWEQ module proteins Talin1, Talin2, Hip1, and Hip12 with actin. Biochemistry 2004, 43:15418-15428.
174. Senetar M.A., Moncman C.L., et al. Talin2 is induced during striated muscle differentiation and is targeted to stable adhesion complexes in mature muscle. Cell Motil. Cytoskeleton 2007, 64:157-173.
175. Shain K.H., Landowski T.H., et al. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 2002, 168:2544-2553.
176. Shattil S.J., Kim C., et al. The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell Biol. 2010, 11:288-300.
177. Shaw Y.J., Yang Y.T., et al. Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J. Med. Chem. 2004, 47:4453-4462.
178. Shintani Y., Maeda M., et al. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am. J. Respir. Cell Mol. Biol. 2008, 38:95-104.
179. Siegel D.H., Ashton G.H., et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am. J. Hum. Genet. 2003, 73:174-187.
180. Smith S.J., Mccann R.O. A C-terminal dimerization motif is required for focal adhesion targeting of Talin1 and the interaction of the Talin1 I/LWEQ module with F-actin. Biochemistry 2007, 46:10886-10898.
181. Sommers C.L., Walker-Jones D., et al. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res. 1989, 49:4258-4263.
182. Sommers C.L., Byers S.W., et al. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res. Treat. 1994, 31:325-335.
183. Staley C.A., Parikh N.U., et al. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ. 1997, 8:269-274.
184. Stewart D.A., Cooper C.R., et al. Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod. Biol. Endocrinol. 2004, 2:2.
185. Stoeltzing O., Liu W., et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 2003, 104:496-503.
186. Tadokoro S., Shattil S.J., et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003, 302:103-106.
187. Tantivejkul K., Kalikin L.M., et al. Dynamic process of prostate cancer metastasis to bone. J. Cell. Biochem. 2004, 91:706-717.
188. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
189. Thiery J.P., Acloque H., et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
190. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13:513-609.
191. Thomas J.W., Cooley M.A., et al. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J. Biol. Chem. 1999, 274:36684-36692.
192. Tozer G.M., Kanthou C., et al. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5:423-435.
193. Trikha M., Zhou Z., et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 2004, 110:326-335.
194. Tu Y., Wu S., et al. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell 2003, 113:37-47.
195. Turner C.E., Pavalko F.M., et al. The role of phosphorylation and limited proteolytic cleavage of talin and vinculin in the disruption of focal adhesion integrity. J. Biol. Chem. 1989, 264:11938-11944.
196. Uhlik M.T., Temple B., et al. Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J. Mol. Biol. 2005, 345:1-20.
197. Ussar S., Wang H.V., et al. The Kindlins: subcellular localization and expression during murine development. Exp. Cell Res. 2006, 312:3142-3151.
198. Vinogradova O., Haas T., et al. A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc. Natl. Acad. Sci. USA 2000, 97:1450-1455.
199. Vlodavsky I., Goldshmidt O., et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin. Cancer Biol. 2002, 12:121-129.
200. Watanabe N., Bodin L., et al. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin alphaIIbbeta3. J. Cell Biol. 2008, 181:1211-1222.
201. Webb D.J., Parsons J.T., et al. Adhesion assembly, disassembly and turnover in migrating cells-over and over and over again. Nat. Cell Biol. 2002, 4:E97-E100.
202. Wegener K.L., Partridge A.W., et al. Structural basis of integrin activation by talin. Cell 2007, 128:171-182.
203. Wennerberg K., Armulik A., et al. The cytoplasmic tyrosines of integrin subunit beta1 are involved in focal adhesion kinase activation. Mol. Cell. Biol. 2000, 20:5758-5765.
204. Wu C. Migfilin and its binding partners: from cell biology to human diseases. J. Cell Sci. 2005, 118:659-664.
205. Wu K.J., Zeng J., et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol. Sin. 2009, 30:1162-1168.
206. Xu J., Lamouille S., et al. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19:156-172.
207. Yamaguchi H., Woods N.T., et al. SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis. J. Biol. Chem. 2008, 283:19112-19118.
208. Yan B., Calderwood D.A., et al. Calpain cleavage promotes talin binding to the beta 3 integrin cytoplasmic domain. J. Biol. Chem. 2001, 276:28164-28170.
209. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
210. Zavadil J., Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774.
211. Zavadil J., Cermak L., et al. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 2004, 23:1155-1165.
212. Zhang D., Pier T., et al. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels-a pharmacodynamic study. Invest. New Drugs 2007, 25:49-55.
213. Zhang X., Jiang G., et al. Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat. Cell Biol. 2008, 10:1062-1068.
214. Zhao J., Guan J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009, 28:35-49.
215. Zhao Y., Yan Q., et al. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem. Funct. 2008, 26:571-577.
216. Zoltan-Jones A., Huang L., et al. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J. Biol. Chem. 2003, 278:45801-45810.